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SHORT COMMENTARY
Effect of maternal
supplementation with fish oil
during pregnancy and lactation
on allergy development in
childhood
Allergic diseases have increased rapidly during
the past few decades, and both environmental
and genetic factors appear to play a role. For
example, observational studies have found
associations between maternal fish intake
during pregnancy and protection against aller-
gic disease in their offspring (1). Oily fish is
rich in omega-3 long-chain polyunsaturated
fatty acids (LCPUFAs), and several attempts
has been made to influence allergic develop-
ment in offspring by providing maternal sup-
plementation with fish oil during pregnancy
and/or lactation.
In a double-blind randomised controlled
trial in Link€oping, Sweden, from 2003 to 2005,
145 pregnant mothers at risk of having infants
with allergies were given either omega-3
LCPUFA supplementation or a soya bean oil
placebo from gestational week 25 until three
months after they gave birth. The children were
followed up clinically at three, six, 12 and
24 months of age (2). At 12 months of age,
maternal fish oil supplementation was associ-
ated with a lower prevalence of food allergy,
immunoglobulin E (IgE)-associated eczema,
sensitisation to egg and any positive skin prick
test. At 24 months of age, no associations were
found between maternal fish oil supplementa-
tion and allergic diseases or sensitisation (2).
In this issue of Acta Paediatrica, a follow-
up study by Warstedt et al. (3) aimed to
examine the association between maternal
omega-3 LCPUFA supplementation, omega-3
LCPUFA proportions in breast milk and
allergic diseases at two years of age. Higher
proportions of omega-3 LCPUFAs were
observed in the breast milk of the
supplemented mothers and were associated
with lower levels of IgE-associated eczema
and food reactions in the first two years
of life.
This randomised controlled study was con-
ducted more than 10 years ago, yet only allergy
diagnoses at two years of age were reported. It is
well known that allergic phenotypes may change
throughout the first years of life and that eczema
and food allergies are most prevalent around one
and two years of age, while respiratory allergy
usually appears for the first time after four years
of age. In young children, wheezing phenotypes
are often caused by viral respiratory infections
rather than allergies. For example, a child
diagnosed with eczema at two years of age may
be free from allergic symptoms later in child-
hood. Hence, it would have been of great interest
to evaluate the association between maternal
omega-3 LCPUFA supplementation and allergy
in these children when they were older than two
years of age.
Furthermore, the authors conclude that the
proportions of the omega-3 LCPUFAs eicos-
apentaenoic acid and docosahexaenoic acid in
breast milk were related to a protective effect of
the development of IgE-associated allergic
diseases in infancy. Based on their results,
they suggest that supplementation must occur
both during pregnancy and lactation (3). We
have previously proposed that the perinatal
period of life is of high importance for later
allergy development (4). In the study by
Warstedt et al. (3), the effect of supplementa-
tion of omega-3 LCPUFA on allergy was not
evaluated separately during pregnancy and
lactation. Hence, it is difficult to draw conclu-
sions about the role of the omega-3 LCPUFA
content in breast milk per se. The effect of
supplementation may be set already during
pregnancy, and there is no clear evidence from
this study of a direct effect of supplementation
during lactation, as children who received high
breast milk proportions of omega-3 LCPUFA
also received high levels of omega-3 LCPUFA
during pregnancy.
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